Gilead Sciences Inc

Healthcare
$72.70
-0.32(0.44%) 1D
1D
1W
1M
1Y
3Y
5Y

Performance

Open PricePrev. CloseVolumeAvg. Volume
$73.18$72.706,2547,970,531

Fundamentals

Market Cap$90.56B
P/B Ratio4
P/E Ratio16
Enterprise Value$109.46B
Div. Yield4.24%
Book Value17.88
EPS(TTM)1.75
ROENA
Understand Fundamentals

About the Company

Founded in 1987, Gilead Sciences Inc. is a biopharmaceutical company that develops, researches and commercialises drugs. It is headquartered in Foster City, California, and as of 2020, employs 11,800 individuals across its research centres and other operations. The company is best known for Harvoni and Sovaldi, its Hepatitis C cures. Some of the locations where it conducts operations include Miami, Santa Monica, La Verne, Seattle, Emeryville etc. As of 2020, it has or is developing medicines for issues like liver diseases, cardiovascular, inflammation/respiratory, haematology/oncology and COVID-19 along with few others. Some of its medicines include Atripla, Genvoya, Complera, Veklury, Harvoni, Vosevi, Trodelvy, Macugen, Letairis, Yescarta, etc. The company has 3 Breakthrough Therapy Designations; 12 NDA/BLA/MAA, P3 and Registrational P2 trials; 42 Clinical Stage Programs; and 17 NMEs via In-Licensing, Options, and Product Acquisitions. It is testing potential treatment compounds of HBV, emerging virus, cell therapy, inflammatory diseases, non-cell therapy, HIV and fibrotic diseases. It entered the Fortune 500 family in 2009 and holds the 140th place as of 2020. Gilead is a component in the S&P 500, S&P 100, NASDAQ 100 and NASDAQ Biotechnology indices as of the same year. It trades in the NASDAQ stock exchange under the ticker symbol GILD. In 2020, Forbes has recognised it in its Global 2000, Best Employers For Diversity and World’s Best Employers lists. Gilead Sciences was founded in 1987 as Oligogen by a medical doctor named Michael L. Riordan. Back then its primary focus was on antiviral medicines and started its early research on small strands of DNA. Its name soon changed to Gilead Sciences after the ancient Balm of Gilead that was known for its healing properties. Its first substantial acquisition was in 1999 with NeXstar Pharmaceuticals. Between 2003 and 2020, it acquired companies like Triangle Pharmaceutical in 2003, Myogen, Inc., Raylo Chemicals and Corus Pharma, Inc. in 2006, CV Therapeutics, Inc. in 2009, CGI Pharmaceuticals in 2010, Calistoga Pharmaceuticals in 2011, Phenex Pharmaceuticals in 2015, Nimbus Apollo, Inc. in 2016, Immunomedics in 2020, etc.;
OrganisationGilead Sciences Inc
IndustryDrug Manufacturers—General
HeadQuartersFoster City, CA

Company Financials

*All values are in Million $
No Graph Data To Display
Quarterly
Yearly

Similar Stocks

COMPANYMARKET PRICECLOSE PRICEMARKET CAP
Invest the way you want
Join millions of Indians who trust and love Groww
Explore Products
ⓒ 2016-2024 Groww. All rights reserved, Built with in India
MOST POPULAR ON GROWWVERSION - 4.7.6
STOCK MARKET INDICES:  S&P BSE SENSEX |  S&P BSE 100 |  NIFTY 100 |  NIFTY 50 |  NIFTY MIDCAP 100 |  NIFTY BANK |  NIFTY NEXT 50
MUTUAL FUNDS COMPANIES:  GROWWMF |  SBI |  AXIS |  HDFC |  UTI |  NIPPON INDIA |  ICICI PRUDENTIAL |  TATA |  KOTAK MAHINDRA |  DSP |  CANARA ROBECO |  SUNDARAM |  MIRAE ASSET |  BANDHAN |  FRANKLIN TEMPLETON |  PPFAS |  MOTILAL OSWAL |  INVESCO |  EDELWEISS |  ADITYA BIRLA SUN LIFE |  LIC |  HSBC |  NAVI |  QUANTUM |  UNION |  IDBI |  ITI |  MAHINDRA MANULIFE |  360 ONE |  BOI |  TAURUS |  JM FINANCIAL |  PGIM |  SHRIRAM |  BARODA BNP PARIBAS |  QUANT |  WHITEOAK CAPITAL |  TRUST |  SAMCO |  NJ |  BAJAJ